Tamoxifen in Ductal Carcinoma In Situ

Seminars in Oncology

Volumn 33, Issue 6, 2006, Pages 647-649

  Daly, Mary B ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAMMOGRAPHY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; NEOPLASMS, HORMONE-DEPENDENT; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 34547826136     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.08.019     Document Type: Article

References (17)

1. Allred D. Biologic characteristics of ductal carcinoma in situ. In: Silverstein M. (Ed). Ductal Carcinoma In Situ of the Breast (ed 2) (2002), Lippincott Williams & Wilkins, Philadelphia, PA 37-48
2. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 353 (2000) 1993
3. Cuzick J. Treatment of DCIS-Results from clinical trials. Surg Oncol 12 (2003) 213-219
4. Fisher B., Land S., Mamounas E., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28 (2001) 400-418
5. Barnes N.L.P., Boland G.P., Davenport A., et al. Relationship between hormone receptor status and tumor size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg 92 (2005) 429-434
6. Sakorafas G.H., and Farley D.R. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 12 (2003) 221-240
7. Solin L.J., Kurtz J., Fourquet A., et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14 (1996) 754-763
8. Kerlikowske K., Molinaro A., Cha I., et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95 (2003) 1692-1702
9. Allred D.C., Bryant J., Land S., et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of intraductal breast cancer: findings of the NSABP Protocol B-24. Breast Cancer Res Treat 77 (2002) S36 (suppl 1, abstr)
10. UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomized controlled trial. Lancet 362 (2003) 95-102
11. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (2005) 1652-1662
12. Claus E.B., Chu P., Howe C.L., et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70 (2001) 303-316
13. Albonico G., Querzoli P., Ferretti S., et al. Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev 22 (1998) 313-318
14. Collins L.C., and Schnitt S.J. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: Frequency and implications for tamoxifen therapy. Mod Pathol 18 (2005) 615-620
15. Nakhlis F., Lazarus L., Hou N., et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg 201 (2005) 688-694
16. Yen T.W.F., Hunt K.K., Mirza N.Q., et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 100 (2004) 942-949
17. Port E.R., Montgomery L.L., Heerdt A.S., et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8 (2001) 580-585